Browse SPON2

Summary
SymbolSPON2
Namespondin 2, extracellular matrix protein
Aliases DIL1; Mindin; M-spondin; DIL-1; differentially expressed in cancerous and non-cancerous lung cells 1; Spondi ......
Chromosomal Location4p16.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Secreted, extracellular space, extracellular matrix
Domain PF06468 Spondin_N
PF00090 Thrombospondin type 1 domain
Function

Cell adhesion protein that promotes adhesion and outgrowth of hippocampal embryonic neurons. Binds directly to bacteria and their components and functions as an opsonin for macrophage phagocytosis of bacteria. Essential in the initiation of the innate immune response and represents a unique pattern-recognition molecule in the ECM for microbial pathogens (By similarity). Binds bacterial lipopolysaccharide (LPS).

> Gene Ontology
 
Biological Process GO:0001819 positive regulation of cytokine production
GO:0002237 response to molecule of bacterial origin
GO:0002367 cytokine production involved in immune response
GO:0002440 production of molecular mediator of immune response
GO:0002443 leukocyte mediated immunity
GO:0002444 myeloid leukocyte mediated immunity
GO:0002448 mast cell mediated immunity
GO:0002697 regulation of immune effector process
GO:0002699 positive regulation of immune effector process
GO:0002700 regulation of production of molecular mediator of immune response
GO:0002702 positive regulation of production of molecular mediator of immune response
GO:0002718 regulation of cytokine production involved in immune response
GO:0002720 positive regulation of cytokine production involved in immune response
GO:0006909 phagocytosis
GO:0006959 humoral immune response
GO:0007409 axonogenesis
GO:0007411 axon guidance
GO:0008228 opsonization
GO:0009615 response to virus
GO:0009620 response to fungus
GO:0010934 macrophage cytokine production
GO:0010935 regulation of macrophage cytokine production
GO:0019730 antimicrobial humoral response
GO:0019731 antibacterial humoral response
GO:0032496 response to lipopolysaccharide
GO:0032635 interleukin-6 production
GO:0032640 tumor necrosis factor production
GO:0032675 regulation of interleukin-6 production
GO:0032680 regulation of tumor necrosis factor production
GO:0032755 positive regulation of interleukin-6 production
GO:0032760 positive regulation of tumor necrosis factor production
GO:0042742 defense response to bacterium
GO:0043152 induction of bacterial agglutination
GO:0048667 cell morphogenesis involved in neuron differentiation
GO:0050832 defense response to fungus
GO:0051607 defense response to virus
GO:0060907 positive regulation of macrophage cytokine production
GO:0061081 positive regulation of myeloid leukocyte cytokine production involved in immune response
GO:0061082 myeloid leukocyte cytokine production
GO:0061564 axon development
GO:0071216 cellular response to biotic stimulus
GO:0071219 cellular response to molecule of bacterial origin
GO:0071222 cellular response to lipopolysaccharide
GO:0071396 cellular response to lipid
GO:0071706 tumor necrosis factor superfamily cytokine production
GO:0097485 neuron projection guidance
GO:0098542 defense response to other organism
GO:1903555 regulation of tumor necrosis factor superfamily cytokine production
GO:1903557 positive regulation of tumor necrosis factor superfamily cytokine production
Molecular Function GO:0001530 lipopolysaccharide binding
GO:0003823 antigen binding
Cellular Component GO:0005578 proteinaceous extracellular matrix
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-5083635: Defective B3GALTL causes Peters-plus syndrome (PpS)
R-HSA-1643685: Disease
R-HSA-3906995: Diseases associated with O-glycosylation of proteins
R-HSA-3781865: Diseases of glycosylation
R-HSA-392499: Metabolism of proteins
R-HSA-5173214: O-glycosylation of TSR domain-containing proteins
R-HSA-5173105: O-linked glycosylation
R-HSA-597592: Post-translational protein modification
Summary
SymbolSPON2
Namespondin 2, extracellular matrix protein
Aliases DIL1; Mindin; M-spondin; DIL-1; differentially expressed in cancerous and non-cancerous lung cells 1; Spondi ......
Chromosomal Location4p16.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between SPON2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between SPON2 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
29440144Hepatocellular CarcinomaPromote immunity (infiltration)Here we report that, in the tumor microenvironment of hepatocellular carcinoma (HCC), SPON2 not only promotes infiltration of M1-like macrophages but also inhibits tumor metastasis. SPON2-α4β1 integrin signalling activated RhoA and Rac1, increased F-actin reorganization, and promoted M1-like macrophage recruitment. Overall, our findings provide evidence that SPON2 is a critical factor in mediating the immune response against tumor cell growth and migration in HCC.
Summary
SymbolSPON2
Namespondin 2, extracellular matrix protein
Aliases DIL1; Mindin; M-spondin; DIL-1; differentially expressed in cancerous and non-cancerous lung cells 1; Spondi ......
Chromosomal Location4p16.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of SPON2 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolSPON2
Namespondin 2, extracellular matrix protein
Aliases DIL1; Mindin; M-spondin; DIL-1; differentially expressed in cancerous and non-cancerous lung cells 1; Spondi ......
Chromosomal Location4p16.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of SPON2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.7310.253
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-2.0610.495
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.2740.875
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.4490.358
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.6250.783
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.2220.941
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.0380.955
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.0540.969
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.1020.954
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.5380.759
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.6870.494
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.3180.0736
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of SPON2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27730001
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27590001
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.804.81
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.707.71
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916012.5-12.50.52
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59022.2-22.20.505
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolSPON2
Namespondin 2, extracellular matrix protein
Aliases DIL1; Mindin; M-spondin; DIL-1; differentially expressed in cancerous and non-cancerous lung cells 1; Spondi ......
Chromosomal Location4p16.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of SPON2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolSPON2
Namespondin 2, extracellular matrix protein
Aliases DIL1; Mindin; M-spondin; DIL-1; differentially expressed in cancerous and non-cancerous lung cells 1; Spondi ......
Chromosomal Location4p16.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of SPON2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by SPON2.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolSPON2
Namespondin 2, extracellular matrix protein
Aliases DIL1; Mindin; M-spondin; DIL-1; differentially expressed in cancerous and non-cancerous lung cells 1; Spondi ......
Chromosomal Location4p16.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of SPON2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolSPON2
Namespondin 2, extracellular matrix protein
Aliases DIL1; Mindin; M-spondin; DIL-1; differentially expressed in cancerous and non-cancerous lung cells 1; Spondi ......
Chromosomal Location4p16.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of SPON2 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolSPON2
Namespondin 2, extracellular matrix protein
Aliases DIL1; Mindin; M-spondin; DIL-1; differentially expressed in cancerous and non-cancerous lung cells 1; Spondi ......
Chromosomal Location4p16.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between SPON2 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolSPON2
Namespondin 2, extracellular matrix protein
Aliases DIL1; Mindin; M-spondin; DIL-1; differentially expressed in cancerous and non-cancerous lung cells 1; Spondi ......
Chromosomal Location4p16.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting SPON2 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.